Hair cloning is humorously discussed as always being 5-7 years away, with skepticism about its near-term availability. Gene editing to reactivate dormant follicles is suggested as a more likely solution within the next ten years.
Exploring the potential of using verteporfin during hair transplants to minimize scarring and regenerate follicles, as well as discussing a possible standardized protocol for this treatment.
User noticed tiny dots on their head after using 0.5% dutasteride and 8% minoxidil, which others identified as developing hairfollicles. Encouragement was given to continue the treatment.
Hair loss may be linked to blood flow and inflammation, with treatments like Minoxidil, finasteride, and quercetin being discussed. The conversation also mentions the role of 5AR enzyme distribution in hairfollicles.
Exosome injections stimulate hair growth by using exosomes' healing potential to awaken dormant hairfollicles and promote new hair cell creation. The procedure increases scalp blood circulation, encourages collagen and elastin formation, and regenerates hairfollicles, improving hair thickness and quality.
Stem cell hair transplants use stem cells from fat tissue to reactivate inactive hairfollicles, but results are inconsistent and not widely shared. Traditional treatments like finasteride and minoxidil often show better results.
A female user is experiencing minimal regrowth and miniaturized hair after 6 months of treatment with oral minoxidil, spironolactone, and topical minoxidil. She seeks advice on whether she can restore her remaining follicles.
JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hairfollicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.
PP405, a topical LDH inhibitor, has shown to stimulate hairfollicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
Treatments for hair loss, such as using AR receptor blockers and degraders, to see if follicles can regenerate in the long term. The conversation also discusses how hair transplants could be a potential solution.
A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hairfollicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.
The conversation discusses concerns about the potential risk of cancer from creating new hairfollicles through microneedling, due to stem cell division. Specific treatments mentioned include microneedling, caffeine-containing anti-hair loss shampoos, and other unspecified topicals.
Shiseido's S-DSC hair regenerative treatment in Japan focuses on improving existing hair by thickening miniaturized follicles, not creating new ones. There is limited patient feedback and long-term data available.
Testosterone can still cause hair loss even when DHT is blocked by dutasteride, especially if hairfollicles are sensitive. Topical treatments like RU58841 or pyrilutamide may help, but their long-term effectiveness is uncertain compared to dutasteride.
Verteporfin reduces scar tissue in hair transplants but doesn't significantly regrow hairfollicles. More testing is needed to determine its effectiveness.
The conversation discusses difficulty in distinguishing between new hair growth and thinning hair at the temples after using microneedling and a rosemary peppermint topical for four weeks. The advice given is to wait a few months to see if the hairs grow out to determine their nature.
Microneedling is unlikely to damage existing hair if done with a device using a smaller needle count, like a 9-needle cartridge, and a stamping motion. Hairfollicles are deeper than the typical needle penetration depth.
Prostaglandin balance affects hair loss, particularly in conditions like Lichen Planopilaris, where an imbalance can lead to hairfollicle damage. Treatments mentioned include prostaglandin analogs and Pioglitazone HCL, with a focus on maintaining prostaglandin equilibrium for potential hair regrowth.
Researchers at the University of Virginia discovered a new group of stem cells in hairfollicles that could potentially restore hair growth. The findings suggest that activating these stem cells might offer a new way to combat hair loss, though practical treatments are still years away.
A sugar gel called 2-deoxy-D-ribose (2dDR) shows potential for promoting hair regrowth by increasing blood supply to hairfollicles, similar to Minoxidil, but its effectiveness in humans is unproven. It may benefit those who don't tolerate Minoxidil, but it is not a replacement for treatments like Finasteride or RU58841.
Glycosaminoglycans are important for hair growth, and combining minoxidil with tretinoin and Biopeptide-CL may enhance hair growth by boosting glycosaminoglycan levels and improving the hairfollicle environment. Users discussed the potential effectiveness and future of these treatments.
The conversation discusses potential future hair loss treatments, including SCUBE3, hairfollicle cloning, and GT20029, with mentions of past disappointments like CosmeRNA and hopes for treatments like Verteporfin for infinite donor hair.
The post is an update on the user's hair loss journey. They have a strong hairfollicle that has remained unaffected by hair loss for almost 3 years. The user is starting finasteride and using ketoconazole, alfatradiol, and oral castor oil for hair maintenance.
User discusses using Verteporfin for hair regrowth after hair transplant. Replies mention successful follicle regrowth in studies and mice, questioning if it can be replicated in humans.
PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.
PP405 is a promising new treatment for hair loss that activates dormant stem cells in hairfollicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.
Minoxidil alone may not stop hair loss. Finasteride is recommended for androgenic alopecia, as minoxidil doesn't prevent DHT from miniaturizing hairfollicles.
Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hairfollicles and preventing cell death, offering a localized treatment without systemic side effects.
Tretinoin can cause non-telogen hair loss in some men by inducing catagen-like changes in hairfollicles and through retinoid toxicity, especially when used with minoxidil. Some users report hair loss even when using retinoids on the face, while others experience benefits when combined with treatments like finasteride and minoxidil.